Clinical trial
Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy
NCT00307164 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00307164 |
|---|---|
| Title | Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy |
| Official title | A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Lipoatrophy |
| Intervention type | Drug |
| Interventions | NucleomaxX, NucleomaxX placebo |
| Enrollment | 167 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 27, 2006 |
| Last update posted | Nov 4, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: